EP3449257A1 - Verfahren zum nachweis des ursprungs einer infektion - Google Patents
Verfahren zum nachweis des ursprungs einer infektionInfo
- Publication number
- EP3449257A1 EP3449257A1 EP17719610.2A EP17719610A EP3449257A1 EP 3449257 A1 EP3449257 A1 EP 3449257A1 EP 17719610 A EP17719610 A EP 17719610A EP 3449257 A1 EP3449257 A1 EP 3449257A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- infection
- concentration
- bacterial
- att
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims abstract description 71
- 239000002753 trypsin inhibitor Substances 0.000 claims abstract description 84
- 101710081722 Antitrypsin Proteins 0.000 claims abstract description 80
- 230000001475 anti-trypsic effect Effects 0.000 claims abstract description 80
- 230000001580 bacterial effect Effects 0.000 claims abstract description 77
- 239000012634 fragment Substances 0.000 claims abstract description 75
- 208000035143 Bacterial infection Diseases 0.000 claims description 38
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 38
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 208000036142 Viral infection Diseases 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 18
- 206010017533 Fungal infection Diseases 0.000 claims description 16
- 208000031888 Mycoses Diseases 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 description 28
- 239000000523 sample Substances 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 230000009385 viral infection Effects 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 230000002538 fungal effect Effects 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 108010048233 Procalcitonin Proteins 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 7
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 102000016799 Leukocyte elastase Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000004638 bioanalytical method Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000579835 Merops Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100031787 Myosin regulatory light polypeptide 9 Human genes 0.000 description 1
- 101710107065 Myosin regulatory light polypeptide 9 Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108010001059 SPAAT inhibitor Proteins 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 102400000247 Short peptide from AAT Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150037054 aat gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- BULVZWIRKLYCBC-UHFFFAOYSA-N phorate Chemical compound CCOP(=S)(OCC)SCSCC BULVZWIRKLYCBC-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 108010004034 stable plasma protein solution Proteins 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- KIYMLWIZXQPEHU-UKELCRPCSA-N virip Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 KIYMLWIZXQPEHU-UKELCRPCSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
- G01N2333/8125—Alpha-1-antitrypsin
Definitions
- the present invention is in the field of medicine. It relates to a method and kit for determining whether an infection is of bacterial or non-bacterial origin.
- Antibiotic resistance due to the inappropriate use of antimicrobials is one of the most critical public health problems worldwide.
- a major factor underlying the unnecessary use of antibiotics is the lack of rapid and accurate diagnostic tests.
- the early identification of bacterial infections and its differentiation from other types of infection is still a challenge for clinicians.
- PCT procalcitonin
- CRP C-reactive protein
- PCT is produced by the liver and peripheral blood mononuclear cells, modulated by lipopolysaccharides and sepsis- related cytokines.
- CRP is an acute-phase reactant, and CRP level measurements are frequently used to aid in the diagnosis of bacterial infections.
- CRP is synthesized by the liver, mainly in response to IL-6, which is produced not only during infection but also in many types of inflammation. It binds to polysaccharides in pathogens, activating the classical complement pathway.
- PCT and CRP-Tests are prevalent in clinical settings, their accuracy in diagnosing a bacterial infection is heavily questioned and varies between different studies. Also, the clinical benefit for diagnostics and monitoring of therapy is debated as costs for tests are very high.
- the object of the present invention is to provide new suitable markers, methods and means for differentiating a bacterial from a non-bacterial infection with high sensitivity and specificity.
- One aspect of the present invention therefore relates to a method for determining in a patient whether an infection is of bacterial or non-bacterial origin, comprising the steps of determining the concentration of antitrypsin (ATT) and/or of at least one fragment thereof, in a sample that has been taken from said patient, and determining whether said patient suffers from an infection of bacterial or non-bacterial origin based on the concentration of ATT and/or of at least one fragment thereof and designating the infection as of bacterial origin or non-bacterial origin.
- ATT antitrypsin
- the invention further relates to a kit comprising the means for determining the concentration of ATT and/or of at least one fragment thereof in a sample, and the means for comparing the determined concentration of said ATT and/or of at least one fragment thereof with reference concentrations, as well as instructions for carrying out the method and correlating the determined concentrations with the type of infection.
- fragment refers to a proteolytic cleavage product of a respective full-length protein.
- patient refers to a living human or non-human organism that is receiving medical care or that should receive medical care due to a disease, or is suspected of having a disease. This includes persons with no defined illness who are being investigated for signs of pathology. Thus the methods and assays described herein are applicable to both, human and veterinary disease.
- alpha-l-antitrypsin is also referred to as antitrypsin and "ATT”.
- Alpha 1 Antitrypsin or a- 1-antitrypsin (A1AT) is a protease inhibitor belonging to the serpin superfamily. It is generally known as serum trypsin inhibitor.
- Alpha-l-antitrypsin is also referred to as alpha-l-proteinase inhibitor (A1PI) because it inhibits a wide variety of proteases. It protects tissues from enzymes of inflammatory cells, especially neutrophil elastase, and has a reference range in blood of 1.5 - 3.5 g/l, but the concentration can rise manifold upon acute inflammation.
- A1PI alpha-l-proteinase inhibitor
- ATT is cleaved at the reactive center loop (RCL) by target proteases (e.g. neutrophil elastase), as well as non-target proteases (e.g. matrix metalloproteases) (Fig.2). Both reactions lead to a conformational change and a loss of inhibitory activity.
- C-terminal alpha-1 antitrypsin peptide is herein referred to as CAAP48.
- CAAP48 is generated through the cleavage of AAT between Phe352-Leu353 and results in a carboxyl-terminal 42-residue peptide with a mass of 4789 Da, which is bound to the cleaved complex in a non-covalent manner (Fig. 2).
- Variants of this fragment such as VIRIP or C-36 peptide have been identified in several human tissues and body fluids.
- physiological functions such as NK- cell suppression and serine protease protection (C ISPP peptide), extracellular matrix protection by reversible serine protease inhibition (SPAAT), pro- or anti-inflammatory immune modulating functions (C-36 peptide) as well as inhibition of HIV entry (VI RIP) have been reported.
- the terms "threshold”, “threshold value”, “cut-off” and “cut-off value” are used synonymously.
- the optimal cut-off value is defined to be the concentration at which patients are classified into the bacterial or non-bacterial group with the highest sensitivity and specificity.
- a "kit” is a packaged combination optionally including instructions for use of the combination and/or other reactions and components for such use.
- Concentration measurements of AAT and its fragments in combination with the mindful analysis carried out by the inventors, surprisingly revealed an increased proteolytic activity in patients with bacterial infection resulting in high peak intensities of AAT fragments compared to infections of non-bacterial origin.
- the present invention therefore relates to a method for determining in a patient whether an infection is of bacterial or non-bacterial origin, the method comprising determining the concentration of antitrypsin (ATT) and/or of at least one fragment thereof, in a sample that has been taken from said patient, and determining whether said patient suffers from an infection of bacterial or non-bacterial origin based on the concentration of ATT and/or of at least one fragment thereof and designating the infection as of bacterial or non-bacterial origin.
- ATT fragments are substantially elevated in patients suffering from a bacterial infection, compared to patients with a non-bacterial infection (Fig. 1).
- an infection is designated as of bacterial origin if the concentration of at least one ATT fragment is above a certain cut-off value.
- the optimal cut-off value is defined to be the concentration at which patients are classified into the bacterial or nonbacterial group with the highest sensitivity and specificity.
- the infection is designated as of bacterial origin, if the concentration of said at least one ATT fragment is at least 2.5 -fold higher in the patient than a reference concentration.
- concentration is at least 3 -fold higher, more preferred, at least 4 -fold higher and most preferred at least 5 -fold higher than the reference concentration of said at least one ATT fragment thereof.
- a reference concentration in the meaning of the present invention is the median concentration of respective ATT and/or fragments thereof in healthy subjects.
- an infection is designated to be of bacterial origin if the concentration of said at least one ATT fragment is between 2.5 to 7 -fold higher than the reference concentration, more preferably between 3 to 6.5 -fold higher, more preferably between 3.5 to 6 - fold higher, preferably between 4 to 5.5 -fold higher, and most preferably between 4.5 to 5 -fold higher than the reference concentration.
- the protein and/or fragment concentration is measured via mass spectrometry.
- concentrations of said ATT and/or fragments thereof are determined via LC-MS/MS.
- One embodiment of the invention used to quantify said ATT and/or fragments thereof is detailed in the examples.
- the method of the invention can also be used to differentiate between several types of infection and determine their origin.
- said non-bacterial infection is selected from the group comprising viral and fungal infections.
- the present invention relates to a method wherein, if the concentration of said at least one ATT fragment is below a certain cut-off value, the infection is designated as of nonbacterial origin.
- Said non-bacterial origin can be, but is not limited to viral origin or fungal origin.
- the infection is designated as of non-bacterial origin if the concentration of said at least one ATT fragment is not more than 2.5. -fold higher than a reference concentration.
- concentration of the at least one ATT fragment is not more than 2 -fold higher than a reference concentration, most preferably not more than 1.5 -fold higher than a reference concentration.
- an infection is also designated to be of non-bacterial origin if the concentration of said at least one ATT fragment is between 1.2 to 2.4 -fold higher than the reference concentration, preferably between 1.5 to 2.3-fold higher, most preferably between 1.75 to 2 -fold higher than the reference concentration.
- said sample taken from a patient is selected from a group comprising a plasma sample, a serum sample, a whole blood sample, a blood sample or fractions thereof, a lymphatic fluid sample, a urine sample and an extract of any of the aforementioned samples.
- a plasma sample e.g., a plasma sample, a serum sample, a whole blood sample, a blood sample or fractions thereof, a lymphatic fluid sample, a urine sample and an extract of any of the aforementioned samples.
- the method according to the invention also relates to a method in which the concentration of CAAP48 and the SNP-variant CAAP47 is quantified via LC-MS/MS as detailed in the examples.
- the method of quantification of said ATT and/or fragments thereof, such as CAAP48 and/or CAAP47 is not limited to mass spectrometry.
- Figure 1 and 3 show the unexpected results obtained by the inventors, that the CAAP47/48 concentrations are significantly elevated in the blood of patients suffering from a bacterial infection compared to patients suffering from a non-bacterial infection.
- said ATT and/or at least one fragment thereof comprises CAAP48 and/or CAAP47.
- said ATT and/or at least one fragment thereof is CAAP48 and/or CAAP47.
- the present invention therefore relates to a method for determining in a patient whether an infection is of bacterial or non-bacterial origin, the method comprising determining the concentration of CAAP48 and/or CAAP47, in a sample that has been taken from said patient, and determining whether said patient suffers from an infection of bacterial or non-bacterial origin based on the concentration of CAAP48 and/or CAAP47 and designating the infection as of bacterial or non-bacterial origin.
- an infection is designated as of bacterial origin if the concentration of CAAP48 and/or CAAP47 is above a certain cut-off value.
- the optimal cut-off value is defined to be the concentration at which patients are classified into the bacterial or non- bacterial group with the highest sensitivity and specificity.
- the cut-off value for determining that an infection is of bacterial origin is a concentration of CAAP48 and/or CAAP47 of at least 5 ⁇ in the blood of said patient and may deviate depending on the patient analyzed by about 20 %.
- the cut-off value is at least 5 ⁇ , but it can also be at least 6 ⁇ , at least 7 ⁇ , or at least 8 ⁇ .
- the cut-off value for determining that an infection is of bacterial origin is between 4.5 and 8 ⁇ , preferably between 5 and 7.5 ⁇ , more preferably between 5 and 7 ⁇ , also preferably between 5.5 and 6.5 ⁇ between 5.5 and 6 ⁇ , and most preferably between 5 and 5.5 ⁇ .
- the invention also relates to a method in which, if the concentration of said CAAP48 and/or CAAP47 is at least 2.5 -fold higher than a reference concentration, the infection is designated of bacterial origin.
- the concentration is at least 3 -fold higher, even more preferred, at least 4 -fold higher, and most prefera bly at least 5 -fold higher than the reference concentration of said CAAP48 and/or CAAP47.
- an infection is designated to be of bacterial origin if the concentration of said CAAP48 and/or CAAP47 is between 2.5 to 7 -fold higher than the reference concentration, more preferably between 3 to 6.5 -fold higher, more preferably between 3.5 to 6 -fold higher, more preferably between 4 to 5.5 -fold higher most preferred between 4.5 to 5 -fold higher than the reference concentration.
- the CAAP47/48 concentrations are significantly higher in patients suffering from a bacterial infection compared patients suffering from a viral infection.
- the median concentration of CAAP47/48 in the blood of patients with a bacterial infection is much higher compared to patients with a viral infection (Fig. 1).
- the inventors found that the median concentration of CAAP47/48 in the blood of patients with a bacterial infection is 7.97 ⁇ , which is a 4-fold increase compared to patients with a viral infection (Fig. 1).
- the concentration of CAAP47/48 in the blood of patients suffering from a bacterial infection is significantly higher compared patients suffering from a fungal infection.
- the inventors found that the median concentration of CAAP47/48 in patients suffering from a fungal infection is 4.5 ⁇ , compared to 7.97 ⁇ in patients suffering from a bacterial infection (Fig. 3). Therefore, in one embodiment of the method according to the invention, the cut-off value for determining that an infection is of non-bacterial origin is a concentration of CAAP48 and/or CAAP47 of less than 5 ⁇ in the blood of said patient and may deviate depending on the patient analyzed by about 20 %.
- said cut-off value for determining that an infection is of non-bacterial origin is less than 5 ⁇ , preferably less than 4.5 ⁇ , more preferably less than 4 ⁇ .
- the cut-off value for determining that an infection is of non-bacterial origin is between 3.5 and 5 ⁇ , between 3 and 4.5 ⁇ , or between 3.5 and 4 ⁇ .
- the inventors surprisingly found that the concentration of at least one ATT fragment, is clearly lower in patients suffering from a viral or a fungal infection than in patients suffering from a bacterial infection (Fig. 1 and 3).
- the concentration of at least one ATT fragment in patients suffering from a fungal infection is in between the concentration of the at least one ATT fragment in patients suffering from a bacterial and the concentration in patients suffering from a viral infection. Therefore, in one embodiment, the method according to the invention allows not only for the discrimination between bacterial and non-bacterial infections, but also whether a non-bacterial infection is of viral and fungal origin.
- an infection is designated as of fungal origin if the concentration of said at least one ATT fragment is above the cut-off value for designating an infection a viral infection and below the cut-off value for designating an infection as of bacterial origin.
- the infection is designated as to be of fungal origin if the concentration of said at least one ATT fragment is at least 1.5 -fold higher but not more than 2.5. -fold higher than a reference concentration.
- an infection is designated as to be of viral origin if the concentration of said at least one ATT fragment is not more than 1.5 -fold higher than a reference concentration.
- Figure 1 shows, the CAAP47/48 concentrations are significantly higher in patients suffering from a bacterial infection compared patients suffering from a viral infection.
- the cut-off value for determining that an infection is of viral origin is a concentration of CAAP48 and/or CAAP47 of less than 3 ⁇ in the blood of said patient and may deviate depending on the patient analyzed by about 20 %.
- the cut-off value for determining that an infection is of viral origin is less than 3 ⁇ , more preferably less than 2 ⁇ and most less than 1.5 ⁇ .
- the cut-off value for determining that an infection is of viral origin is between 1 and 3 ⁇ , more preferably between 1.5 and 2.5 ⁇ and most prefera bly 2 ⁇ .
- the infection is designated as of viral origin, if the concentration of said CAAP48 and/or CAAP47 is less than 1.5 fold higher than a reference concentration.
- concentration to designate an infection as of viral origin is about the same value as the reference concentration of said CAAP48 and/or CAAP47.
- the CAAP47/48 concentrations are significantly higher in patients suffering from a bacterial infection compared patients suffering from a fungal infection and even higher than in patients suffering from a viral infection.
- the inventors found that the median concentration of CAAP47/48 in the blood of patients with a fungal infection is 4.5 ⁇ .
- an infection is designated as of fungal origin if the concentration of CAAP47/48 is below the cut-off value of designating an infection as to be of bacterial origin and above the cut-off value of designating an infection as to be of viral origin. Therefore, in one embodiment of the method according to the invention, an infection is designated as to be of fungal origin if the concentration of CAAP48 and/or CAAP47 in the blood of said patient is between 1.5 ⁇ and 5 ⁇ and may deviate depending on the patient analyzed by about 20 %.
- the concentration of CAAP48 and/or CAAP47 for designating an infection as to be of fungal origin is between 5 ⁇ and 1.5 ⁇ , preferably between 2 ⁇ and 4.5 ⁇ , more preferably between 2.5 ⁇ and 4 ⁇ and most preferably between 3 ⁇ and 3.5 ⁇ .
- the infection is designated as of fungal origin, if the concentration of said CAAP48 and/or CAAP47 is less than 2.5 -fold higher than a reference concentration but more than 1.5 -fold higher than a reference concentration.
- the infection is designated as of fungal origin if the concentration of CAAP47/48 is 2 -fold higher than a reference concentration.
- a sample is taken at one or more of the following time points: when the subject is first admitted to a medical institution or in the ambulance, when the subject is in the emergency room, when the subject is in the intensive care unit, before treatment, after initiation of treatment, 24 hours after initiation of treatment, 48 hours after initiation of treatment and/or 72 hours after initiation of treatment.
- the method according to the invention can also be used to monitor the success of treatment of a patient suffering from an infection.
- it can be used to monitor the success of antimicrobial treatment, e.g. with antibiotics.
- the method according to the invention relates to a method for monitoring the success of treating a patient suffering from an infection with a certain drug, comprising the steps of determining the concentration of antitrypsin (ATT) and/or of at least one fragment thereof, in a sample that has been taken from said patient, and associating the levels of ATT and/or fragments thereof with a positive or a negative response to said certain drug.
- ATT antitrypsin
- Said positive response is given if the level of ATT increases during drug treatment and/or if the level of ATT fragments decreases during drug treatment.
- said drug can be an antimicrobial drug, e.g. an antibiotic.
- Said ATT fragments may comprise CAAP47/48.
- the method according to the invention relates to a method for monitoring the success of treating a patient that suffering from an infection with a drug, comprising the steps of:
- Said positive response is given if the level of ATT increases during drug treatment and/or if the level of ATT fragments decreases during drug treatment.
- said drug can be an antimicrobial drug, e.g. an antibiotic.
- Said ATT fragments may comprise CAAP47/48.
- the method according to the invention can be used to determine the appropriate treatment and/or therapy. For example, it can be used to determine the right medication before and during treatment. Therefore, the method according to the invention may prevent harmful side- effects, toxicity and allergic reactions due to inappropriate drug treatment and/or therapy. Moreover, serious complications can be prevented in patients and the healing process can be accelerated. This may also significantly reduce the costs of therapy. In case of treating a patient suffering from an infection, the inappropriate prescription of antibiotics may be prevented, thus preventing the spread of antibiotic resistance.
- the invention also relates to a method of medical decision making for individual patient therapy in a subject suffering from an infection, comprising the steps of, determining the concentration of antitrypsin (ATT) and/or of at least one fragment thereof, in a sample that has been taken from said patient, and associating the levels of ATT and/or fragments thereof with a certain choice of therapy.
- ATT antitrypsin
- the method according to the invention can be used in medical decision making for individual patient therapy in a subject suffering from an infection.
- it can be used to determine whether a patient should be treated with antibiotics.
- the invention also relates to a method of medical decision making for individual patient therapy in a subject related to the severity of the disease.
- the invention relates to a method of medical decision making for individual patient therapy related to the severity of the disease by monitoring therapy response in a subject to a certain drug.
- drug can be an antimicrobial-drug, e.g. antibiotics. Therefore, the invention also relates to a method of medical decision making for individual patient therapy in a subject suffering from an infection, comprising the steps of,
- Said positive response to therapy is given if the level of ATT increases during drug treatment and/or if the level of ATT fragments decreases during drug treatment.
- said therapy may comprise the treatment with antimicrobial drugs, which can be antibiotics.
- Said ATT fragments may comprise CAAP47/48.
- the present invention also relates to a kit for determining whether an infection is of bacterial or non-bacterial origin, comprising means for determining the concentration of ATT and/or of at least one fragment thereof in a sample, means for comparing the determined concentration of said ATT and/or of at least one fragment thereof with reference concentrations, and instructions for carrying out the method and relating the determined concentrations with the type of infection.
- the means for determining the concentration of said ATT and/or of at least one fragment thereof is an antibody specific for ATT and/or for at least one fragment thereof.
- said fragment is CAAP48 and/or CAAP47 and said antibody is specific for CAAP48 and/or CAAP47.
- the means for comparing the determined concentrations comprise standard data showing the correlation between the concentration of said ATT and/or at least one fragment thereof contained in samples and the origin of infection.
- the present invention also relates to a kit as described above, wherein said infection of nonbacterial origin is an infection selected from the group comprising viral and fungal infections.
- the present invention also relates to a kit according to the invention, wherein said sample is selected from a group comprising a plasma sample, a serum sample, a whole blood sample, a blood sample or fractions thereof, a lymphatic fluid sample, a urine sample and an extract of any of the aforementioned samples.
- the method and kit according to the invention can be used not only for determining if an infection is of bacterial or non-bacterial origin, but also for the monitoring of treatment of a patient.
- Such treatment may comprise the treatment of an infection such as a bacterial, viral or fungal infection.
- the monitoring of treatment can relate to the monitoring of treatment of a patient with an antimicrobial drug, such as antibiotics.
- the invention also relates to a kit for diagnosis of a bacterial infection and/or predicting the outcome of treatment with a certain drug and/or the monitoring of treatment of a patient suffering from an infection comprising, an antibody, an aptamer, or another target specific molecule specific for ATT and/or fragments thereof, standard data showing the correlation between the amounts of ATT and/or fragments thereof contained in samples and prognosis, and a manual.
- the invention relates to an LC-MS/MS kit for diagnosing a bacterial infection and/or predicting the outcome of treatment in a patient with a certain drug and/or the monitoring of treatment of a patient suffering from an infection, wherein the concentrations of ATT and/or fragments thereof are re guaranteed by LC-MS/MS. These concentrations are compared to standard data sets. Examples
- Example 1 Patient groups and characteristics
- HIV patients Nine, six and eight HIV patients were enrolled with virus titers of ⁇ 100, 100 - 10000 and > 10000 cop/ml, respectively. Healthy volunteers were included for AAT genotype and phenotype correlation and for the cell experiments. Patients less than 18 years old, pregnant or lacking informed consent were excluded. The study and all protocols were approved by the local ethics committee.
- Peptides were synthesized by solid phase peptide synthesis and purified by HPLC with greater 95% purity.
- peptides were synthesized automatically by a standard Fmoc [N-(9- fluorenyl)methoxycarbonyl] protocol by manual SPPS or on an EPS221 peptide synthesizer (Intavis Bioanalytical Instruments AG, Cologne, Germany).
- Fmoc-amino acids 5 equiv
- HBTU equiv
- N-methylmorpholine/DMF (1:1) for 5—15 min (double couplings).
- Fmoc removal was effected by treating the resin twice with piperidine in DMF (20 %). All CAAP48 an immunomodulatory sepsis biomarker deprotection and coupling steps were followed by intensive washings with DMF and dichlorometane (CH2CI2), alternately. Peptide cleavage and deprotection was accomplished with reagent K (trifluoroacetic acid (TFA)/water/phenol/thioanisole/ethanedithiol 82.5:5:5:5:2.5) for 4 h at room temperature. The crude peptides were precipitated with diethyl ether, centrifuged, and washed several times with diethyl ether.
- TFA trifluoroacetic acid
- the yields of the crude peptides varied between 60 - 70 %.
- the crude peptides were purified by semipreparative reversed-phase HPLC with a Shimadzu LC- 8A system equipped with a C18 column (Knauer Eurospher 100, Berlin, Germany).
- the gradient elution system was 0.1 % TFA in water (eluent A) and 0.1 % TFA in acetonitrile/water (9:1, eluent B).
- the peptides were eluted with a gradient of 0 - 50 % eluent B in 120 min and a flow rate of 10 ml/min. The peaks were detected at 220 nm.
- the peptide was eluted with solvent A (H20 + 0.1% FA) and solvent B (AcN + 0.1% FA), starting at 90% A for 2 min, followed by a 6 min linear gradient to 40% A, 5 min 40% A, 1 min linear gradient to 90% A, 6 min 90% A with a flow rate of 200 ⁇ /min.
- the column oven was set 38°C.
- Two peptides were chosen for fragmentation: the 5 fold charged CAAP48 peptide (4789.7 Da) at 958.9 Da and the 6 fold charged CAAP48 peptide at 799.3 Da.
- transitions could be detected at high intensities: 799.3/873.6, 799.3/243.4, 799.3/314.3, 958.9/1091.8.
- MS parameters were CXP:27, DP:60, EP:10, CAD:12, CU :22, GS1:40:, GS2:50, IS:5500, TEM :600.
- CE was optimized for the single fragments (874.4: 27, 1091.5: 33, 243.4: 39, 314.3: 28).
- For detection of the CAAP47 peptide (4775.7 Da) equivalent transitions were chosen at 797.0/ 873.6, 797.0/ 243.4, 956.167/ 1088.4 and 797.0/ 314.3.
- Recovery was determined by spiking three standard concentrations in EDTA plasma of donor plasma. Autosampler stability was determined by measuring three samples 8 times in a time range of 24 hours. Freeze/thawCAAP48 an immunomodulatory sepsis biomarker stability was determined by thawing and freezing two samples on 8 consecutive days. Parallelism was determined by diluting a sample consecutively in buffer and referring the concentrations of the dilutions to the original concentration.
- Validation resulted in a linear calibration curve in a range of 2 - 200 ng ⁇ l with a coefficient of determination of 1.
- the LOD was 2.03 ng/ ⁇
- Intraday accuracy was determined to be 0.98, 1.13 and 0.88 for the three respective concentrations.
- Interday accuracy was determined to be 1.07, 1.01 and 0.95.
- Intraday precision was 4, 11 and 11%, interday precision 15, 13 and 10%.
- FIG. 1 CAAP47/48 concentrations are significantly elevated in the blood of patients suffering from a bacterial infection.
- CAAP47/48 concentrations are significantly higher in patients suffering from a bacterial infection compared to patients suffering from a viral infection.
- the median concentration for bacterial infection is 7.97 ⁇ , which is a 4-fold increase compared to patients with a viral infection.
- Fig. 2 Cleavage sites in the AAT reactive center loop (RCL).
- Fig. 3 Median CAAP47/48 concentrations are significantly lower in the blood of patients suffering from a fungal infection than in patients suffering from a bacterial infection.
- CAAP47/48 concentrations are significantly higher in patients suffering from a bacterial infection compared to patients suffering from a fungal infection.
- the median concentration for fungal infection is 4.5 ⁇ .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16167699.4A EP3239712B1 (de) | 2016-04-29 | 2016-04-29 | Verfahren zur ermittlung des ursprungs einer infektion |
PCT/EP2017/060040 WO2017186842A1 (en) | 2016-04-29 | 2017-04-27 | Method for determining the origin of an infection |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3449257A1 true EP3449257A1 (de) | 2019-03-06 |
Family
ID=56072205
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16167699.4A Active EP3239712B1 (de) | 2016-04-29 | 2016-04-29 | Verfahren zur ermittlung des ursprungs einer infektion |
EP17719610.2A Pending EP3449257A1 (de) | 2016-04-29 | 2017-04-27 | Verfahren zum nachweis des ursprungs einer infektion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16167699.4A Active EP3239712B1 (de) | 2016-04-29 | 2016-04-29 | Verfahren zur ermittlung des ursprungs einer infektion |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP3239712B1 (de) |
WO (1) | WO2017186842A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473650A1 (de) * | 2017-10-18 | 2019-04-24 | Universitätsklinikum Jena | Antikörper zur spezifischen detektion von caap47/48-ffragmenten |
EP4224163A1 (de) * | 2022-02-02 | 2023-08-09 | Universitätsklinikum Jena | Diagnose von sepsis und des systemischen entzündungsreaktionssyndroms durch ein quantitatives lc-/ms-verfahren |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2656150T3 (es) * | 2011-11-14 | 2018-02-23 | Universitätsklinikum Jena | Diagnóstico de la sepsis y del síndrome de respuesta inflamatoria sistémica |
-
2016
- 2016-04-29 EP EP16167699.4A patent/EP3239712B1/de active Active
-
2017
- 2017-04-27 EP EP17719610.2A patent/EP3449257A1/de active Pending
- 2017-04-27 WO PCT/EP2017/060040 patent/WO2017186842A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP3239712A1 (de) | 2017-11-01 |
EP3239712B1 (de) | 2021-03-10 |
WO2017186842A1 (en) | 2017-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5960717B2 (ja) | 自閉症の診断、治療におけるバイオマーカーおよびその使用 | |
EP3456744B1 (de) | Untersuchung und behandlung von bradykininvermittelten erkrankungen | |
Mareš et al. | Use of cystatin C determination in clinical diagnostics | |
JP2014506244A6 (ja) | 自閉症の診断、治療におけるバイオマーカーおよびその使用 | |
EP2795325B1 (de) | Verfahren zur diagnose von morbus alzheimer | |
CN106574930A (zh) | 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法 | |
EP3521828A1 (de) | Verfahren zur diagnose eines hereditären angioödems | |
JP5348595B2 (ja) | 線維筋痛症の検査法 | |
EP3239712B1 (de) | Verfahren zur ermittlung des ursprungs einer infektion | |
US6660482B1 (en) | Inter-alpha-trypsin inhibitor as a marker for sepsis | |
US10989720B2 (en) | Method for clinically and pathologically monitoring Alzheimer's disease through concentration of amyloidbeta in plasma | |
Zhu et al. | The diagnostic and antibiotic reference values of procalcitonin for intracranial infection after craniotomy | |
US11035865B2 (en) | Serologic assay of liver fibrosis | |
Conti et al. | Pigment epithelium‐derived factor is differentially expressed in peripheral neuropathies | |
EP3535587B1 (de) | Massenspektrometriebasierte verfahren zur detektion zirkulierender histone h3 und h2b in plasma von sepsispatienten oder patienten mit septischem schock (ss) | |
EP2743701B1 (de) | Verfahren zum nachweis von infektionen an stellen einer operation | |
US20240012010A1 (en) | Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat | |
WO2014104305A1 (ja) | プレセプシン測定による炎症性腸疾患の診断 | |
WO2007017293A2 (en) | Method for screening for proteases and their substrates | |
EP3473650A1 (de) | Antikörper zur spezifischen detektion von caap47/48-ffragmenten | |
Liao | Development of Methods for Characterization of Elastolytic Activity: Towards the Development of New Therapeutics for the Treatment of Alpha-1-Antitrypsin Deficiency | |
JP2020139901A (ja) | スティーブンス・ジョンソン症候群及び/又は中毒性表皮壊死症の評価方法、評価のためのデータ取得方法、及び評価用キット | |
AL-Naqeeb et al. | Effect of Covid-19 Infection on kidney Function and some Related Hormones in infected Iraqi people | |
Liori | Salivary biomarkers in Multiple Sclerosis and Autoimmune Hepatitis explored by an integrate top-down and bottom-up platform | |
Said et al. | Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181127 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SCHMERLER, DIANA Inventor name: KIEHNTOPF, MICHAEL |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200228 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |